- Investing.com
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California. As of December 15, 2025, Evoke Pharma, Inc. operates as a subsidiary of QOL Medical, LLC.
Metrics to compare | EVOK | Peers Peers - average of corresponding metrics from companies closely matching EVOK: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVOKPeersSector |
|---|---|---|---|---|
P/E Ratio | −4.5x | 0.0x | −0.6x | |
PEG Ratio | −0.07 | 0.00 | 0.00 | |
Price/Book | 7.1x | 0.0x | 2.6x | |
Price / LTM Sales | 1.6x | 0.0x | 3.4x | |
Upside (Analyst Target) | 63.6% | 0.0% | 41.5% | |
Fair Value Upside | Unlock | 0.0% | 5.5% | Unlock |